Staphylococcus aureus is one of the most important pathogens causing chronic biofilm infections. These are becoming more difficult to treat owing to drug resistance, particularly because S. aureus biofilms limit the efficacy of antimicrobial agents, leading to high morbidity and mortality. In the present study, we screened for inhibitors of S. aureus biofilm formation using a natural product library from the Korea Chemical Bank (KCB). Screening by crystal violet-based biomass staining assay identified hit compounds. Further examination of antibiofilm properties of these compounds was conducted and led to the identification of celastrol and telithromycin. In vitro, both celastrol and telithromycin were toxic to planktonic S. aureus and also active against a clinical methicillin-resistant S. aureus (MRSA) isolate. The effect of the compounds on preformed biofilms of clinical MRSA isolates was evaluated by confocal laser scanning microscopy (CLSM), which revealed the absence of typical biofilm architecture. In addition, celastrol and telithromycin inhibited the production of extracellular protein at selected sub-MIC concentrations, which revealed the reduced extracellular polymeric substance (EPS) secretion. Celastrol exhibited greater cytotoxicity than telithromycin. These data suggest that the hit compounds, especially telithromycin, could be considered novel inhibitors of S. aureus biofilm. Although the mechanisms of the effects on S. aureus biofilms are not fully understood, our data suggest that telithromycin could be a useful adjuvant therapeutic agent for S. aureus biofilm-related infections.

Department of Biomedical Laboratory Science College of Medical Sciences Soonchunhyang University 22 Soonchunhyang ro Shinchang myeon Asan si Chungcheongnam do 31538 Republic of Korea

Department of Medical Science College of Medical Sciences Soonchunhyang University 22 Soonchunhyang ro Shinchang myeon Asan si Chungcheongnam do 31538 Republic of Korea

Zobrazit více v PubMed

Antimicrob Agents Chemother. 1994 May;38(5):1052-8 PubMed

Antimicrob Agents Chemother. 1980 Nov;18(5):699-708 PubMed

N Engl J Med. 2004 Apr 1;350(14):1422-9 PubMed

Lancet. 2006 Sep 2;368(9538):874-85 PubMed

Acta Biomater. 2009 Jan;5(1):63-75 PubMed

Microbiol Immunol. 1994;38(8):615-9 PubMed

Microbiol Mol Biol Rev. 2000 Dec;64(4):847-67 PubMed

Nat Rev Microbiol. 2009 Sep;7(9):629-41 PubMed

Curr Opin Investig Drugs. 2005 Feb;6(2):178-84 PubMed

J Clin Microbiol. 1985 Dec;22(6):996-1006 PubMed

Comp Biochem Physiol A Mol Integr Physiol. 2013 Mar;164(3):447-55 PubMed

JAMA. 2007 Oct 17;298(15):1763-71 PubMed

J Clin Invest. 2003 Dec;112(11):1620-5 PubMed

Clin Microbiol Rev. 2002 Apr;15(2):167-93 PubMed

Acta Med Okayama. 2004 Aug;58(4):207-14 PubMed

Braz J Infect Dis. 2011 Jul-Aug;15(4):305-11 PubMed

PLoS One. 2012;7(11):e49969 PubMed

Chem Biol. 2002 Aug;9(8):859-71 PubMed

J Antimicrob Chemother. 2008 Jan;61(1):26-38 PubMed

Int J Med Microbiol. 2002 Jul;292(2):107-13 PubMed

Lancet. 2001 Jul 14;358(9276):135-8 PubMed

J Med Microbiol. 2002 Apr;51(4):344-9 PubMed

Drug Discov Today. 2003 Feb 15;8(4):168-74 PubMed

J Bacteriol. 2004 Jul;186(14):4665-84 PubMed

Nat Rev Microbiol. 2010 Sep;8(9):623-33 PubMed

N Engl J Med. 2004 Oct 14;351(16):1645-54 PubMed

Antimicrob Agents Chemother. 2014;58(3):1622-9 PubMed

J Mater Sci Mater Med. 2015 Jul;26(7):215 PubMed

J Antimicrob Chemother. 1988 Dec;22(6):777-80 PubMed

Epidemiol Infect. 2013 Jun;141(6):1187-98 PubMed

Emerg Infect Dis. 2001 Mar-Apr;7(2):178-82 PubMed

Biofouling. 2016 Sep 13;32(8):853-60 PubMed

J Microbiol Methods. 2008 Dec;75(3):449-56 PubMed

J Antimicrob Chemother. 2015 Feb;70(2):479-88 PubMed

J Biol Chem. 1951 Nov;193(1):265-75 PubMed

Front Biosci. 2004 Jan 01;9:841-63 PubMed

Emerg Infect Dis. 2001 Mar-Apr;7(2):342-7 PubMed

Expert Rev Anti Infect Ther. 2003 Jun;1(1):45-55 PubMed

PLoS One. 2015 May 28;10(5):e0128098 PubMed

Science. 2009 Jul 10;325(5937):161-5 PubMed